Catalog No.
Product Name
Application
Product Information
Citations
-
Nucleoside Reverse Transcriptase Inhibitor
Stavudine sodium is a nucleoside reverse transcriptase inhibitor (NRTI) primarily utilized for its efficacy against HIV-1 and HIV-2. This compound demonstrates the ability to inhibit mitochondrial DNA replication, reduce NLRP3 inflammasome activation, and modulate the autophagy of Amyloid-β, contributing to its therapeutic potential. Additionally, Stavudine sodium is associated with inducing apoptosis in targeted cells, making it a valuable tool in HIV research and related cellular studies. -
R-isomer of Colchicine
(R)-Colchicine is the R-isomer of Colchicine, a potent inhibitor of tubulin polymerization. It exhibits a strong microtubule-disruptive mechanism, with an IC50 value of 3 nM. In addition to its role as a tubulin inhibitor, (R)-Colchicine acts as a competitive antagonist of the α3 glycine receptors, contributing to its diverse biological activities. This compound is significant in research focused on anti-inflammatory responses, immunosuppression, and treatment strategies for gouty arthritis, particularly by mitigating NSAID-induced intestinal injury through NLRP3 inflammasome inhibition. -
PD-1/PD-L Complex Inhibitor
BMS-202 hydrochloride is a potent inhibitor of the PD-1/PD-L1 complex, exhibiting an IC50 of 18 nM and a KD of 8 μM. This nonpeptidic molecule selectively binds to PD-L1, effectively blocking the interaction between human PD-1 and PD-L1. BMS-202 hydrochloride demonstrates significant antitumor activity, making it a valuable tool for research in immunotherapy and cancer biology. -
COX Inhibitor
Ketorolac hydrochloride is a non-steroidal anti-inflammatory drug (NSAID) that acts as a nonselective inhibitor of cyclooxygenase (COX), with IC50 values of 20 nM for COX-1 and 120 nM for COX-2. It is utilized in the study of various ophthalmic conditions, including allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Additionally, Ketorolac hydrochloride functions as a DDX3 inhibitor, making it relevant for cancer research applications. -
Stable Isotope
Lenalidomide-d4 is a deuterium-labeled derivative of Lenalidomide, functioning as a stable isotope for advanced chemical research. As an orally active immunomodulator, Lenalidomide targets the cereblon (CRBN) ubiquitin E3 ligase, leading to the selective ubiquitination and degradation of transcription factors IKZF1 and IKZF3. This activity is particularly relevant in the context of mature B-cell lymphomas, including multiple myeloma, where Lenalidomide-d4 has been shown to inhibit tumor growth and promote IL-2 release from T cells. This reagent is suitable for studies in drug mechanisms and development within the field of oncology. -
Stable Isotope
Everolimus-13C2,d4 is a stable isotope-labeled derivative of Everolimus, a potent and selective inhibitor of mTOR1. By binding to FKBP-12, Everolimus forms an immunosuppressive complex that effectively inhibits tumor cell proliferation while promoting apoptosis and autophagy. This compound is valuable for research applications in cancer therapy and immunosuppression studies, facilitating tracking and quantification in metabolic and pharmacokinetic investigations. -
STING Agonist
PDIC-NC is a STING agonist that promotes the activation of the STING pathway, leading to enhanced immune responses against tumors. This compound is cytotoxic to tumor cells and induces reactive oxygen species (ROS) production, as well as apoptosis and autophagy. With its specific distribution to lung tissue, PDIC-NC is particularly valuable for research applications focused on lung cancer. -
Anti-inflammatory Agent
Cinnamtannin D1 is a polyphenolic compound recognized for its anti-inflammatory properties, primarily through its immunosuppressive effects. It modulates the Th17/Treg balance by inhibiting AHR expression, subsequently downregulating p-STAT3/RORγt and promoting Treg differentiation via p-STAT5/Foxp3. Cinnamtannin D1 has demonstrated significant protective effects against apoptosis and oxidative stress in INS-1 cells and primary murine islets exposed to palmitic acid. Its efficacy in the collagen-induced arthritis model underscores its potential for research in rheumatoid arthritis. -
EGFRvIII Epitope
EGFRvIII peptide is a synthetic epitope derived from the EGFRvIII variant, specifically designed to bind to MHC I molecules. This peptide is known to induce apoptosis and elicit targeted immune responses against glioblastoma, particularly when used in conjunction with Flagellin B. It is a valuable tool for research in cancer immunotherapy and the development of personalized medicine approaches for glioblastoma treatment. -
Anti-CD20 Antibody
Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 antibody targeting the CD20 antigen on B cells. This antibody exhibits significant pro-apoptotic activity in vitro and mediates both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). In various tumor xenograft models, mAb 1.5.3 demonstrates enhanced anti-tumor efficacy. Additionally, it achieves superior B-cell depletion in lymphoid tissues and bone marrow in primate pharmacodynamic studies, making it a valuable tool for research into B-cell malignancies. -
Neddylation Inhibitor
Keap1-Nrf2-IN-4 is a potent neddylation inhibitor that targets the Keap1-Nrf2 pathway. It exhibits significant anti-proliferative activity against MGC-803 gastric cancer cells, with an IC50 value of 2.55 µM. Additionally, Keap1-Nrf2-IN-4 effectively inhibits cell migration and induces apoptosis in these cancer cells, contributing to tumor growth suppression while exhibiting minimal toxicity. This compound is valuable for research into cancer therapies and the regulation of oxidative stress responses. -
CRBN Modulator
AG6033 is a novel modulator of the cereblon (CRBN) protein. This compound effectively suppresses various tumor cell lines by influencing the interactions between CRBN and key antitumor target proteins, leading to the degradation of GSPT1 and IKZF1. AG6033 has demonstrated a CRBN-dependent cytotoxic effect, making it a valuable tool for research in cancer biology and the development of targeted therapies. -
COX Inhibitor
Meloxicam sodium is a selective cyclooxygenase (COX) inhibitor, primarily targeting COX-2 with an IC50 of 0.49 μM while exhibiting a higher IC50 of 36.6 μM for COX-1. This non-steroidal anti-inflammatory agent is capable of crossing the blood-brain barrier, making it suitable for research applications involving central nervous system inflammation and pain management. Meloxicam sodium is widely utilized in studies assessing the efficacy of anti-inflammatory therapies. -
TLR3 Agonist
Polyinosinic-polycytidylic acid potassium is a synthetic analog of double-stranded RNA that acts as an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors. This reagent is utilized to stimulate innate and adaptive immune responses, serving as an effective vaccine adjuvant while also modifying the tumor microenvironment. Additionally, Polyinosinic-polycytidylic acid potassium can induce apoptosis in cancer cells, making it a valuable compound for cancer research and immunotherapy studies. -
COX-1/2 Inhibitor
Taraxerol acetate is an inhibitor of COX-1 and COX-2, exhibiting IC50 values of 116.3 μM and 94.7 μM, respectively. This compound demonstrates notable anticancer properties and has been shown to induce apoptosis in cancer cells. Taraxerol acetate is valuable for research applications focusing on inflammation, pain relief, and cancer treatment mechanisms. -
Anti-inflammatory/Anticancer/Neuroprotective Agent
5-OH-HxMF is a hydroxylated polymethoxyflavone that exhibits significant anti-inflammatory and anticancer properties. Additionally, it demonstrates neuroprotective and neurotrophic activities, making it a valuable reagent for research in inflammation, cancer biology, and neurodegenerative diseases. Its multifaceted biological effects support its use in studies aimed at understanding and developing therapies for various pathologies. -
Triple IKZF1/2/3 Degrader
MGD-22 is a molecular glue and an orally active degrader of the IKZF1/2/3 proteins, with DC50 values of 8.33 nM, 9.91 nM, and 5.74 nM, respectively. This compound exhibits significant anti-proliferative effects on various hematological cancer cell lines and induces apoptosis in these cells. Additionally, MGD-22 demonstrates robust anti-tumor efficacy in mouse models with NCI-H929 or WSU-DLCL-2 xenografts. It is a valuable tool for investigating hematological malignancies, particularly multiple myeloma (MM), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL). -
Anti-Inflammatory Agent
Picrasidine I is a dimeric alkaloid known for its anti-inflammatory properties, primarily acting through the modulation of key signaling pathways. It induces cell cycle arrest and apoptosis by downregulating the ERK and Akt pathways. Additionally, Picrasidine I inhibits the activation of MAPKs and NF-κB, reduces reactive oxygen species generation, and suppresses the expression of c-Fos and NFATc1, making it a valuable tool for research in inflammation and osteoclastogenesis. -
Anti-inflammatory Agent/Anticancer Agent
Cryptolepine is a multi-potent alkaloid that serves as an anti-inflammatory and anticancer agent. It functions primarily as an inhibitor of c-Myc, mTOR, NF-κB, HIF-1, and MAPK while activating AMPKα1/2, leading to various biological effects including DNA intercalation and inhibition of topoisomerase II. These activities result in disrupted mitochondrial dynamics and induction of apoptosis in cancer cells. Cryptolepine shows promise in research applications focusing on tumors such as melanoma and hepatocellular carcinoma, as well as in studies related to malaria, inflammatory diseases, and diabetes. -
Anti-Inflammatory Compounds
Anti-inflammatory agent 47 is a potent anti-inflammatory and antioxidant compound that targets inflammatory pathways. It inhibits the release of intracellular reactive oxygen species (ROS) and nitric oxide (NO), thereby suppressing neuronal apoptosis through the modulation of inflammatory and apoptotic signaling cascades. This compound is applicable in research focused on neurodegenerative diseases, particularly Parkinson's Disease (PD). -
Anticancer/Anti-inflammatory Agent
Perezone is a sesquiterpenoid benzoquinone derived from the roots of Acourtia species, acting as an anticancer and anti-inflammatory agent. It effectively inhibits the proliferation of leukemia cell line K-562 and human glioma cell line U-251, with an IC50 of 6.83 μM. Furthermore, Perezone upregulates the expression of apoptosis-related genes, including caspase 3, 8, and 9, while also exhibiting significant antioxidant and anti-inflammatory properties. This compound is of interest in cancer research and potential therapeutic applications. -
Antitumor/Anti-inflammatory Agent
Antitumor agent-56 is a triptolide derivative that functions primarily as an antitumor and anti-inflammatory agent. This compound demonstrates significant inhibitory effects on melanoma proliferation while also exhibiting nitric oxide release activities. Antitumor agent-56 is suitable for various research applications in cancer biology and therapeutic development. -
Anti-CD37 Antibody
BI-836826 is a chimerized IgG1 monoclonal antibody targeting CD37. This antibody exhibits both antibody-dependent cell-mediated cytotoxicity (ADCC) and direct pro-apoptotic effects, making it a valuable tool for investigating chronic lymphocytic leukemia. Its unique properties facilitate research into therapeutic applications and mechanisms of action related to CD37 in lymphoid malignancies. -
TLR9 Inhibitor
ODN 20844 is a TLR9 inhibitor designed to disrupt Toll-like receptor-mediated immune responses. As a guanine-modified inhibitory oligonucleotide, it specifically targets TLR7 and TLR9, leading to a reduction in immune cell activation. This compound is useful for research applications focused on modulating immune pathways and studying immune-related diseases. The sequence of ODN 20844 is 5'-TCCTGGCGc7GGGAAGT-3'. -
TLR7 Agonist
TLR7 Agonist 3 acts as an effective agonist of Toll-like receptor 7 (TLR7), playing a significant role in the immune response modulation. This compound is utilized primarily in cancer research to explore its potential therapeutic effects in tumor immunity and the activation of anti-tumor responses. Its ability to stimulate TLR7 pathways makes it a valuable tool for investigating the mechanisms of immune activation and evaluating novel cancer treatments. -
TLR7/8 Agonist
TLR7/8 Agonist 3 is a potent dual agonist of Toll-like receptors 7 and 8, designed to enhance the immune response against viral infections and tumors. This compound demonstrates significant biological activity through the activation of innate immune pathways, stimulating the production of pro-inflammatory cytokines. Research applications include immunotherapy and the study of host-pathogen interactions, making it a valuable tool for investigating TLR-mediated signaling and immune modulation. -
TLR7 Agonist
BBIQ is an imidazoquinoline compound that acts as a potent and selective agonist for Toll-like receptor 7 (TLR7), exhibiting an EC50 of 59.1 nM in human TLR7. This compound serves as an effective vaccine adjuvant, significantly enhancing innate immune responses. BBIQ is valuable for research applications focused on immunology and vaccine development, facilitating the exploration of TLR7-mediated signaling pathways. -
TLR7 Agonist
Imiquimod maleate is a selective toll-like receptor 7 (TLR7) agonist known for its immune response-modulating properties. It demonstrates significant antiviral and antitumor efficacy in vivo, making it a valuable compound in the study of various conditions. Research applications include the investigation of external genital and perianal warts, cancer, and COVID-19. -
TLR7 Agonist
AZD8848 is a selective agonist of toll-like receptor 7 (TLR7) designed for research applications in asthma and allergic rhinitis. By activating TLR7, this compound enhances immune responses, making it a valuable tool for studying innate immunity and developing therapeutic strategies for related respiratory conditions. -
Anti-Inflammatory Agent
2,4′-Dihydroxybenzophenone acts as an anti-inflammatory agent by targeting the hydrophobic pocket of MD2, effectively inhibiting the dimerization of TLR4. This compound demonstrates significant biological activity by suppressing LPS-induced mitochondrial reactive oxygen species (mtROS) production and attenuating the inflammatory response through downregulation of pro-inflammatory mediators, including MyD88, p-IRAK4, and NF-κB. Additionally, 2,4′-Dihydroxybenzophenone serves as an effective UV absorber, enhancing its utility in research on oxidative stress and inflammation. -
TLR7/8 Agonist
TLR7/8 Agonist 4 is a potent agonist targeting Toll-like receptor 7 and 8. This compound enhances the activation of immune responses, exhibiting significant anti-cancer activity. Its efficacy makes it a promising tool for research in cancer immunotherapy and the study of innate immune signaling pathways. -
TLR8 Antagonist
CU-115 is a potent TLR8 antagonist with an IC50 of 1.04 µM, demonstrating selectivity for TLR8 over TLR7 (IC50 > 50 µM). This compound effectively decreases the production of pro-inflammatory cytokines, including TNF-α and IL-1β, in R-848 activated THP-1 cells. CU-115 is suitable for research applications focusing on TLR8 signaling pathways and inflammatory responses. -
TLR7 Agonist
E104 is a potent and selective TLR7 agonist that activates immune responses through Toll-like receptor 7. This compound enhances the activity of mouse macrophages and human peripheral blood mononuclear cells (hPBMCs), making it valuable in immuno-oncology research. E104's potential for use in antibody-drug conjugate (ADC) technology further supports its application in eliciting robust anticancer effects, contributing to the development of innovative cancer therapies. -
TLR7/TLR8 Inhibitor
BMS905 is a potent dual inhibitor of Toll-like receptors 7 and 8, exhibiting IC50 values of 0.7 nM and 3.2 nM, respectively. This compound effectively inhibits IL-6 production induced by TLR7 or TLR8 activation in both human and mouse whole blood. BMS905 serves as a valuable tool for investigating the role of these receptors in autoimmune diseases, particularly lupus. -
TLR7/8 Agonist
AXC-715 trihydrochloride is a dual agonist of Toll-like receptors 7 and 8 (TLR7/8). This compound enhances immune responses and can be utilized in the synthesis of antibody-adjuvant immunoconjugates, particularly for constructs targeting programmed death-ligand 1 (PD-L1). Its ability to stimulate TLR pathways makes AXC-715 a valuable tool for immunotherapy research and the development of therapeutic antibodies. -
Anti-inflammatory Agent
Regaloside C is an anti-inflammatory agent that exhibits antioxidant properties by scavenging ABTS and DPPH free radicals. It targets multiple molecular pathways, including TNF-α, MMP-2, ERα, AKT1, TLR4, and HSP90-α. This compound is relevant for research focused on inflammatory diseases and may provide insights into therapeutic approaches for managing chronic inflammation. -
TLR7 Agonist
Bropirimine is an orally active Toll-like receptor 7 (TLR7) agonist. It has been shown to inhibit RANKL-induced osteoclast differentiation in mouse bone marrow-derived macrophages, highlighting its potential role in modulating bone metabolism. Additionally, Bropirimine exhibits dose-dependent inhibitory effects on colony formation in cultured KK-47 and 724 cells, making it a valuable tool for cancer research. This compound is relevant for studies investigating cancers and bone metabolic disorders such as osteoporosis. -
TLR7/8 Agonist
PVP-037.2 is a TLR7/8 agonist that activates the immune response through the stimulation of Toll-like receptors. This compound enhances vaccine-induced TH1-type immune responses, leading to increased production of antigen-specific antibodies, particularly IgG1 and IgG2c. PVP-037.2 is valuable for research applications focused on immunology, vaccine development, and the modulation of adaptive immune responses. -
TLR7 Agonist
SM-324405 is a potent TLR7 agonist with an EC50 of 50 nM, exhibiting pEC50 values of 7.3 for human TLR7 and 6.6 for rat TLR7. This compound is particularly useful in immunological research focused on allergic diseases. As an antedrug, SM-324405 is designed to be locally active and is rapidly metabolized to an inactive form upon systemic circulation, effectively mitigating the risk of systemic toxicity while maintaining agonistic activity in targeted environments. -
TLR Agonist
3D-Monophosphoryl Lipid A-5 is a potent TLR agonist that enhances the immunogenicity of vaccines when used as an adjuvant. This compound stimulates innate immune responses, promoting the activation of various immune cells and cytokine production. It is valuable in research applications focused on vaccine development and immunotherapy, offering insights into the modulation of immune responses. -
TLR8 Agonist
TLR8 agonist 5 is a potent agonist of Toll-like receptor 8 (TLR8), demonstrated by an EC50 of 20 nM in the HEK-Blue hTLR8 cell line. This compound effectively stimulates the immune response, making it a valuable tool for research in immunology and inflammation studies. Its ability to activate TLR8 highlights its potential applications in therapeutic development targeting immune-related pathways. -
TLR7 Agonist
1V209 is a Toll-like receptor 7 (TLR7) agonist that exhibits anti-tumor effects through the activation of the TLR7 signaling pathway. This compound can be conjugated with various polysaccharides to enhance its water solubility, thereby improving its efficacy while maintaining low toxicity. 1V209 is suitable for research applications aimed at understanding immune responses and developing cancer immunotherapies. -
TLR Inhibitor
ODN 24991, a guanine-modified inhibitory oligonucleotide, functions as an inhibitor of Toll-like receptors TLR3, TLR7, and TLR9. By disrupting TLR-mediated immune cell signaling, ODN 24991 serves as a valuable tool for investigating immune responses. The compound is particularly useful in research aimed at understanding the role of these TLRs in inflammation and immune regulation. ODN 24991 sequence: 5'-C-C-T-G-G-C-c7rGm-G-G-G-3'. -
TLR7/8 Agonist
D18 is a dual agonist for Toll-like receptors 7 and 8 (TLR7/8), exhibiting EC50 values of 24 nM and 10 nM, respectively. This immune modulator enhances PD-L1 expression through epigenetic mechanisms, thereby increasing tumor sensitivity to PD-1/PD-L1 blockade. D18 demonstrates significant immune activation and anti-tumor effects, making it valuable in cancer research, including studies focused on colon cancer. Additionally, D18 serves as a cytotoxin for the synthesis of antibody-drug conjugate HE-S2. -
TLR7/8 Agonist
AXC-715 hydrochloride is a dual agonist targeting TLR7 and TLR8. It demonstrates significant immunomodulatory activity, making it a valuable tool in the development of antibody-adjuvant immunoconjugates. This compound can be utilized to enhance the efficacy of therapies targeting programmed death-ligand 1 (PD-L1) by linking it to one or more adjuvants, advancing research in cancer immunotherapy and immune response modulation. -
TLR4/NF-κB Inhibitor
TLR4/NF-κB-IN-1 is a selective inhibitor of the TLR4/NF-κB signaling pathway, demonstrating significant anti-inflammatory properties. This compound exhibits the ability to penetrate the blood-brain barrier, making it suitable for studies involving neuroinflammation. In murine models, TLR4/NF-κB-IN-1 effectively reduces acute neuroinflammation induced by lipopolysaccharides (LPS) while downregulating the expression of TLR4, phosphorylated NF-κB, and phosphorylated IκB-α proteins, providing a valuable tool for researching neuroinflammatory processes and their therapeutic modulation. -
TLR8 Antagonist
TLR8 antagonist-1 is a selective antagonist targeting Toll-like receptor 8 (TLR8). It effectively inhibits TLR8-mediated inflammatory responses and associated signaling pathways, including the recruitment of MyD88 and the activation of NF-κB and IRF pathways. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research in inflammation and immune response modulation. -
TLR7 Agonist
BNT411 is a selective TLR7 agonist known for its ability to stimulate the production of interferon-alpha (IFNa) both in vivo and in vitro. This compound exhibits anticancer properties, making it a valuable tool in cancer research, particularly for non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC). Its mechanism of action and efficacy in activating immune responses make it a key reagent for investigating cancer immunotherapy. -
TLR7/8 Antagonist
TLR7/8 antagonist 2 is a potent antagonist specifically targeting Toll-like receptors 7 and 8, with IC50 values of 4.9 nM and 0.6 nM, respectively. This compound is essential for studying the role of TLR7 and TLR8 in autoimmune diseases, such as systemic lupus erythematosus, where their inappropriate activation contributes to pathogenesis. TLR7/8 antagonist 2 holds significant potential for advancing research in the field of autoimmune disorders. -
TLR7/8 Agonist
TLR7/8 Agonist 6 is a potent agonist of Toll-like receptors 7 and 8, exhibiting IC50 values of 0.18 μM and 5.34 μM, respectively. As an imidazoquinoline derivative, this compound plays a crucial role in enhancing immune responses. It is particularly valuable in the investigation of immunomodulatory therapies for infectious diseases, cancer, and autoimmune disorders.
